z-logo
Premium
Polymorphonuclear myeloid‐derived suppressor cells attenuate allergic airway inflammation by negatively regulating group 2 innate lymphoid cells
Author(s) -
Cao Yingjiao,
He Yumei,
Wang Xiangyang,
Liu Yongdong,
Shi Kun,
Zheng Zheng,
Su Xue,
Lei Aihua,
He Juan,
Zhou Jie
Publication year - 2019
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/imm.13040
Subject(s) - innate lymphoid cell , immunology , myeloid derived suppressor cell , immune system , allergic inflammation , inflammation , myeloid , suppressor , cytokine , interleukin 13 , innate immune system , biology , cancer research , interleukin 4 , medicine , cancer
Summary Hyperactivation of the type 2 immune response is the major mechanism of allergic asthma, in which both group 2 innate lymphoid cells ( ILC 2s) and type 2 helper T (Th2) cells participate. Myeloid‐derived suppressor cells ( MDSC s) alleviate asthma by suppressing Th2 cells. However, the potential effects of MDSC s on the biological functions of ILC 2s remain largely unknown. Here, we examined the roles of MDSC s ( MDSC s) in the modulation of ILC 2 function. Our results showed that polymorphonuclear ( PMN )‐ MDSC s, but not monocytic (M‐) MDSC s, effectively suppressed the cytokine production of ILC 2s both in vitro and in vivo , thereby alleviating airway inflammation. Further analyses showed that cyclo‐oxygenase‐1 may mediate the suppressive effects of PMN ‐ MDSC s on ILC 2 responses. Our findings demonstrated that PMN ‐ MDSC s may serve as a potent therapeutic target for the treatment of ILC 2‐driven allergic asthma.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom